benzimidazole has been researched along with sorafenib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Korzeniecki, C; Priefer, R | 1 |
| Elmorsy, MA; Gomaa, RM; Mostafa, AS | 1 |
| Chuang, YT; Hsu, MH; Liao, YJ; Liu, CL; Suk, FM; Wang, JP | 1 |
1 review(s) available for benzimidazole and sorafenib
| Article | Year |
|---|---|
Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
Topics: Humans; Models, Molecular; Molecular Structure; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Signal Transduction | 2021 |
2 other study(ies) available for benzimidazole and sorafenib
| Article | Year |
|---|---|
Design and synthesis of 2-phenyl benzimidazole derivatives as VEGFR-2 inhibitors with anti-breast cancer activity.
Topics: Benzimidazoles; Binding Sites; Breast Neoplasms; Cell Line; Cell Survival; Doxorubicin; Drug Design; Female; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Sorafenib; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2019 |
Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Benzimidazoles; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Mice, Inbred NOD; Pyrrolidines; Sorafenib; Xenograft Model Antitumor Assays | 2019 |